婴儿型半球胶质瘤的分子诊断、治疗与预后系统研究:164例个体患者数据Meta分析
该研究汇总164例婴儿型半球胶质瘤(IHG)患者(155例来自文献检索,9例由合作者提供),中位诊断年龄3.4个月,95%无转移,86.5%存在RTK基因融合。3年无事件生存率49.5%,总生存率79.6%,多变量分析显示仅手术无辅助治疗及术后残留肿瘤与死亡风险增加相关。结论提示IHG为融合驱动肿瘤,治疗应侧重降低手术并发症并提高手术成功率。
要点
- IHG多见于婴儿,95%无转移,86.5%存在RTK基因融合(ALK最常见占47%)。
- 3年EFS为49.5%,OS为79.6%;肿瘤进展和颅内出血为主要死因。
- 仅手术无辅助治疗及术后残留肿瘤与死亡风险增加相关。
核心结论
- IHG是融合驱动的婴幼儿肿瘤,即使进展后仍可存活,最佳初始治疗尚未确立,治疗应聚焦降低手术并发症和提高手术成功率。
研究设计与样本
- 个体患者数据Meta分析,共纳入164例IHG患者,其中155例通过系统文献检索获得,9例由合作者提供。
主要发现
- 所有肿瘤均为半球性,中位诊断年龄3.4(0-52)个月,95%无转移。
- 142例(86.5%)存在RTK基因融合:ALK 67/142(47%)、NTRK1/2/3 32/142(22.5%)、ROS1 29/142(20.4%)、MET 13/142(9.2%)、ABL2 1/142(0.7%)。
- 64%患者接受手术联合辅助化疗,20%仅手术,8%手术联合靶向治疗,5例接受放疗。
- 3年无事件生存率49.5%[40.7-60.2],总生存率79.6%[72.1-87.9]。
- 22例死亡,最常见死因为肿瘤进展(8/22,36%)和颅内出血(5/22,23%)。
临床怎么用
- 对IHG患者应重视手术安全性与切除程度,以降低早期死亡风险并提高手术成功率。
- 分子检测应涵盖RTK基因融合(ALK、NTRK1/2/3、ROS1、MET、ABL2)以指导诊断与潜在靶向治疗。
局限性
- 原文未明确报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Due to the novelty and rarity of infant-type hemispheric glioma (IHG), optimal treatment and factors determining clinical outcomes are yet to be established. METHODS: We curated a series of 164 patients with IHG; 155 identified by methodical literature search and nine additional patients contributed by collaborators. RESULTS: All tumors were hemispheric, diagnosed at a median age of 3.4 (0-52) months, and frequently (95%) non-metastatic. One hundred forty-two (86.5%) tumors harbored fusions involving receptor tyrosine kinase (RTK) genes (ALK [67/142, 47%], NTRK1/2/3 [32/142, 22.5%], ROS1 [29/142, 20.4%], MET [13/142, 9.2%], and ABL2 [1/142, 0.7%]). Sixty-four percentage, 20%, and 8% of patients were treated with surgery and adjuvant chemotherapy, surgery-only, and surgery plus targeted therapy, respectively. Five patients received radiation. Three-year event-free survival (EFS) and overall survival (OS) was 49.5% [40.7-60.2] and 79.6% [72.1-87.9], respectively. Twenty-two patients succumbed to disease, of which tumor progression (8/22, 36%) and intra-cranial hemorrhage (5/22, 23%) were the most common causes. Multivariate analysis showed that the factors most associated with an increased risk of death were no treatment except for surgery and presence of residual tumor after definitive surgery. These findings present a challenging dichotomy where surgery is both a serious risk factor for early death and, when successful, a benefit. CONCLUSIONS: Together, these findings show that IHG is a fusion driven tumor of the very young that is survivable even after progression. While optimal primary therapy for patients with IHG has yet to be established, the findings of this meta-analysis suggest treatment should focus on lowering surgical morbidity and improving its success.
引用
- Chavaz L, Bagchi A, Dhanda SK, et al. A systematic study of molecular diagnosis, treatment, and prognosis in infant-type hemispheric glioma: An individual patient data meta-analysis of 164 patients. Neuro Oncol. 2026. PMID: 41206756. doi:10.1093/neuonc/noaf264
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。